Trump's 100% Pharma Tariffs Draw Industry Fury as Experts Warn of Higher Costs, Delayed Treatments

On April 2, President Donald Trump announced sweeping 100% tariffs on patented pharmaceutical products and ingredients imported into the United States, triggering immediate backlash from industry groups who say the policy will harm patients while failing to achieve its stated goals.

The tariffs, imposed under Section 232 national security authority, will take effect in 120 days for large companies and 180 days for smaller firms. Commerce Secretary Howard Lutnick justified the move by claiming America's reliance on pharmaceutical imports threatens national security, a rationale the industry flatly rejects.

"The reality is that any tariffs on America's medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments, all while doing nothing to enhance our national security," said John Crowley, CEO of the Biotechnology Innovation Organization (BIO).

Exemptions Reveal Political Favoritism

The policy is riddled with carve-outs that undermine its purported national security justification. Sixteen major pharmaceutical companies, including Pfizer, Eli Lilly, and MSD, are exempt from tariffs until 2029 because they signed pricing agreements with the White House under the Most Favored Nation (MFN) framework. Companies that pledge to move production to the US face only a 20% tariff rate and have four years to follow through before the full 100% kicks in.

Generics and biosimilars, which account for roughly 90% of American prescriptions, are not subject to the tariffs at all. The European Union, Japan, Korea, Switzerland, Liechtenstein, and the United Kingdom are also exempt due to separate trade agreements.

According to ING senior economist Diederik Stadig, the countries actually hit by the 100% rate include Singapore, India, and China, none of which currently export substantial volumes of branded pharmaceuticals to the US. "The economic impact will therefore be negligible," Stadig wrote in a research note. "Rather, the tariff is geopolitical in nature and should be seen as a shot across the bow for more intense competition between the US and China in biotech and pharma."

China Anxiety Drives Policy, Not Supply Chain Reality

The tariffs are part of a broader Trump administration campaign to counter China's growing dominance in pharmaceutical development. GlobalData analysis from October 2025 found that China now accounts for one-fifth of global drug development, with one-third of all new molecules in global pipelines originating from Chinese companies.

Western pharmaceutical giants are pouring billions into licensing deals with Chinese biotechs, a trend that has alarmed Washington. In January 2026, Trump enacted the BIOSECURE Act, which prevents certain Chinese biotechs and manufacturers from accessing US funding or collaborating with American pharma companies that use federal dollars.

"We believe that the next Pfizer will be Chinese rather than American or European," Stadig said. "US policymakers on both sides of the aisle have realised that China is a real threat to US dominance in biopharmaceutical innovation."

Trump cited supply chain vulnerabilities in his tariff announcement, noting that the FDA reports approximately 53% of patented pharmaceutical products distributed in the US are manufactured abroad. He argued that life-saving medications could be limited during global supply chain disruptions caused by geopolitical or economic crises, pointing to ongoing Middle East conflicts that have disrupted trade routes.

Industry Warns of Self-Inflicted Harm

Pharmaceutical trade groups are united in their condemnation of the tariffs, warning that the policy will backfire on American patients and researchers.

"Tariffs divert scarce resources away from research and development, weaken American biotech against China's rising industry, and ultimately, harm the health and economic well-being of Americans," Crowley said.

Stephen Ubl, CEO of The Pharmaceutical Research and Manufacturers of America (PhRMA), added: "We need smart policies to ensure that the US remains the best place in the world to discover and manufacture affordable, lifesaving medicines. Tariffs will undermine this important goal."

The exemptions for companies that signed White House pricing deals raise questions about whether the tariffs are designed to extract political concessions rather than genuinely address supply chain security. Meanwhile, the exclusion of generics and biosimilars means the tariffs will disproportionately affect newer, more expensive branded medications, potentially driving up costs for patients with complex conditions who rely on cutting-edge treatments.

As the 120-day implementation window begins, the pharmaceutical industry is bracing for a policy that critics say prioritizes political theater over sound economic strategy, all while patients face the prospect of higher drug prices and delayed access to new therapies.